Compare American International Group Inc (AIG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? American International Group Inc trades at $76.4 (market cap $40.42B), while State Street SPDR S&P Biotech ETF trades at $159.3. The key difference: American International Group Inc pays a 2.59% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, American International Group Inc nearer its low. Which is the better fit depends on your goals.
| AIG | XBI | |
|---|---|---|
Market Cap | $40.42B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $86.59 | $164.28 |
52-Week Low | $71.89 | $86.92 |
Enterprise Value | $48.06B | — |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.42, down 1.53% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with $2.11 EPS versus $1.89 expected, driven by robust underwriting income. Revenue for 2025 was $26.77B with net income of $3.10B, yielding an 11.12% net margin. The stock carries a P/E of 14.11 and a consensus analyst price target of $89.00, suggesting potential upside from current levels.
The outlook for AIG is mixed; solid earnings performance and a diversified insurance portfolio support growth, but competitive pricing pressure and investment income headwinds pose risks. With 39% of analysts rating it a Buy, the stock appears undervalued relative to its price target, though near-term catalysts may be limited amid broader market volatility.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
